FDA Approves METHYLPHENIDATE HYDROCHLORIDE — KVK-TECH, INC.

FDA approved KVK-TECH, Inc.’s abbreviated new drug application (ANDA) for methylphenidate hydrochloride, ramping up generic competition for the ADHD treatment. The approval is expected to bolster market inventory and check pricing pressure for the stimulant, solidifying KVK-TECH’s portfolio in the central nervous system space.